Dermatol. praxi. 2013;7(1):6-10
Alopecia areata
- 1 Klinika chorob kožních a pohlavních LF UP a FN Olomouc
- 2 Dermatologická ambulance Mohelnice, Dermatovenerologické oddělení, Šumperská nemocnice, a. s., Šumperk
Alopecia areata (AA) is a non-scarring hair loss disease that affects both children and adults. This condition is common autoimmune
disease, the ethiopathogenesis is not fully understood. AA is commonly manifested by well-circumscribed patchy areas of complete
hair loss on the scalp and other body parts. In severe cases, alopecia areata can progress to complete loss of all body hair. While not
a life threatening condition, alopecia areata is nevertheless serious because of the psychologically and sociologically devastating
effects the hair loss can have on the victim. Course is unpredictable, therapeutical effect is very individual and the available therapies
are often disappointing. So new therapeutical possibilities are desirable. In the article case reports with successfull anthralin therapy
and diphencypron therapy of alopecia areata are mentioned.
Keywords: alopecia areata, ethiology, treatment, anthralin, diphencypron
Published: April 1, 2013 Show citation
References
- Paus R, Nickoloff BJ, Ito T. A ´hairy´ privilege. Trends Immunol. 2005; 26: 32-40.
Go to original source... 
Go to PubMed... - Arenberger P, a kol. Klinická trichologie. Praha. Maxdorf 2002: 51-89.
- Gilhar A, Etzioni A, Paus R. Alopecia areata. N. Engl. J. Med. 2012; 366: 1515-1525. Go to original source... Go to PubMed...
- Michalíková H. Léčba alopecie. Klin. Farmakol. Farm. 2006; 20: 211-214.
- Rudnicka L, Olszewska M, Rakowska A, et al. Trichoscopy: a new method for diagnosing hair loss. J.of drugs in Dermatol. 2008; 7: 651-654. Go to original source...
- Dy LC, Whiting DA. Histopathology of alopecia areata, acute and chronic: why is it important to the clinician? Dermatol. Ther. 2011; 24: 369-374. Go to original source... Go to PubMed...
- Kar BR, Handa S, Dogra S, et al. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J. Am., Acad. Dermatol. 2005; 52: 287-290. Go to original source... Go to PubMed...
- Dawber R, Van Neste D. Hair and scalp disorders. 2nd ed. London, Martin Dunitz 1997: 169-190.
- Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. BMJ 1983; 287: 1015-1017. Go to original source... Go to PubMed...
- Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J. Am. Acad. Dermatol. 1987; 16: 730-736. Go to original source... Go to PubMed...
- Burgdorf WHC, Plewig G, Wolff HH, Landthaler M. Braun - Falco´s Dermatology, 3th Edition, Springer 2009: p. 1052. Go to original source...
- Cotellessa C, Peris K, Caracciolo E, et al. The use of topical diphencyclopropenone for the treatment of extensive alopecia areata. JAAD 2001; 44(1): 73-76. Go to original source... Go to PubMed...
- Hengge UR. Topische Immunomodulation in der Dermatologie, Zetschrift Für Hautkrankheiten 2002; 77(3): 116-130. Go to original source...
- Ohlmeier MC, Traupe H, Luger TA, et al. Topical immunotherapy with diphencyclopropenone of patients with alopecia areata - a large study on 142 patients with a self-controlled design. JEADV. 2011; 26(4): 503-507. Go to original source... Go to PubMed...
- Sotiaridis D, Patsatsi A, Lazaridou E, et al. Topical immunotherapy with diphencyclopropenone in the treatment of chronic extensive alopecia areata. Clin. Exp. Dermatol. 2007; 32(1): 45-48.
- Schmoeckel C, Weissmann I, Plewig G, et al. Treatment of alopecia areata by anthralin-induced dermatitis. Arch. Dermatol. 1979; 115: 1254-1255. Go to original source... Go to PubMed...
- Ferran M, Calvet J, Amirall M, et al. Alopecia areata as another immune-mediated disease developedin patients treated with tumour necrosis factor-? blocker agents: report of five cases and review of the literature. J. Eur. Acad. Dermatol. Venereol. 2011; 25: 479-484. Go to original source... Go to PubMed...